Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 12/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | SELE | P16581 | 1/20 | 0.30 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12981204 | 0.86 | CHRM2 (0.41) | CHRM2CHRM1TACR1 | |
| SCHEMBL12982524 | 0.83 | CHRM2 (0.40) | CHRM2CHRM1TACR1SLC6A4ICAM1 | |
| SCHEMBL12982489 | 0.82 | SLC6A2 (0.34) | CHRM2CHRM1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2445811 | 0.81 | P2RY1 (0.33) | TACR1MAOAMAOBTAAR1 | |
| SCHEMBL10316662 | 0.78 | MAOA (0.35) | SLC6A4SLC6A3MAOAMAOBTAAR1 | |
| SCHEMBL11890684 | 0.78 | CHRM2 (0.40) | CHRM2CHRM1TACR1SLC6A4SLC6A2 | |
| SCHEMBL15043643 | 0.78 | SLC6A4 (0.45) | CHRM2CHRM1TACR1SLC6A4SLC6A2 | |
| SCHEMBL12981503 | 0.76 | TACR1 (0.63) | TACR1SLC6A4 | |
| SCHEMBL12981604 | 0.75 | SLC6A4 (0.36) | SLC6A4SLC6A2SLC6A3MAOAMAOB | |
| SCHEMBL12981197 | 0.74 | CHRM2 (0.32) | CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | claimed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | claimed |
| CN-102666490-A | Aminopyridine compound | UBE INDUSTRIES | 2012-09-12 | — | — | CN | claimed |
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| CN-102666490-A | Aminopyridine compound | UBE INDUSTRIES | 2012-09-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | PTGIS, QDPR, PTGIR | CHRM2 55/4885CHRM1 65/4885TACR1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.